Hormonal Acne & Skin — The Complete Clinical Guide
Hormonal acne and skin — the complete clinical guide
Hormonal acne is among the most commonly treated yet most consistently mismanaged skin conditions in clinical practice. The standard approach — contraceptive pill, topical retinoids, antibiotics — addresses the downstream expression of a hormonal imbalance without investigating its cause. This article covers the complete hormonal picture: the specific hormones involved, their mechanisms of action on skin, what drives them out of range, and what a clinical investigation should include.
Androgens and sebum production
Sebaceous glands are directly regulated by androgens — primarily testosterone and its more potent derivative dihydrotestosterone (DHT). Both bind to androgen receptors in sebaceous gland cells, stimulating sebocyte proliferation and sebum secretion. DHT is produced locally in the skin from testosterone via the enzyme 5-alpha reductase, which means serum testosterone levels can be normal while DHT-driven sebum overproduction continues at the skin level.
Elevated androgens — whether from PCOS, congenital adrenal hyperplasia, late-onset adrenal hyperplasia, or relative androgen excess following decline of oestrogen at perimenopause — produce excess sebum that blocks the follicular canal, creating the anaerobic environment colonised by Cutibacterium acnes. The inflammatory response to C. acnes — not the bacterium itself — produces the pustular and cystic lesions characteristic of inflammatory acne.
Sex hormone binding globulin (SHBG) is the transport protein that binds and renders androgens biologically inactive. Low SHBG — produced by insulin resistance, hypothyroidism, elevated insulin and excessive alcohol consumption — increases free androgen availability even when total androgen levels appear normal on standard pathology. Assessment of free testosterone and SHBG together is therefore essential and is frequently omitted from standard GP panels.
Insulin resistance and skin
The connection between insulin resistance and acne is one of the most well-established relationships in dermatological research, yet it remains underutilised clinically. High circulating insulin stimulates IGF-1 (insulin-like growth factor 1) production, which acts synergistically with androgens on sebaceous glands and additionally promotes keratinocyte proliferation and follicular hyperkeratosis — the plugging of the follicular canal that precedes acne formation.
A landmark 2012 study by Smith et al. demonstrated that a low glycaemic load diet reduced inflammatory acne lesion counts by 51% over 12 weeks compared to a high glycaemic load control, with simultaneous reductions in free androgen levels and improvements in insulin sensitivity. This study established the dietary-hormonal-skin axis as a legitimate clinical target and remains the most cited dietary intervention trial in acne research.
Fasting insulin and the HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) index are the most practical markers for assessing insulin resistance in skin cases. HbA1c alone is insufficient — it reflects average blood glucose over three months but misses the postprandial insulin spikes that drive IGF-1-mediated sebaceous stimulation in individuals with normal fasting glucose.
Oestrogen, perimenopause and collagen
Oestrogen has broadly protective effects on skin — it stimulates collagen synthesis, maintains skin hydration through hyaluronic acid production, supports barrier function and has anti-inflammatory properties. Oestrogen receptors (ERalpha and ERbeta) are expressed throughout the epidermis and dermis, making the skin highly sensitive to oestrogen decline.
During perimenopause, oestrogen levels begin to decline erratically — often several years before menopause — producing measurable changes in skin structure. A 2023 study in Menopause: The Journal of The Menopause Society found that skin collagen content decreases by approximately 30% in the first five years following menopause, with a further 2% annual decline thereafter. Skin hydration decreases by approximately 25% and barrier function deteriorates, increasing transepidermal water loss and susceptibility to irritant contact dermatitis.
The same oestrogen decline that drives collagen loss can also paradoxically worsen acne in perimenopausal women through relative androgen excess — as oestrogen declines, the previously balanced androgen-oestrogen ratio shifts toward androgen dominance, producing late-onset acne in women who may never have experienced significant acne in their youth.
Cortisol and inflammatory skin conditions
The skin has its own peripheral HPA (hypothalamic-pituitary-adrenal) axis — keratinocytes, melanocytes, fibroblasts and sebaceous gland cells all express CRH receptors and can produce cortisol locally in response to stress signals. Psychological stress activates both the central HPA axis and this peripheral skin stress response simultaneously.
Acute cortisol elevation temporarily increases skin barrier permeability, reduces antimicrobial peptide production and activates mast cells, triggering the immediate skin reactions to stress that most people recognise — flushing, hives, eczema flares and acne breakouts. Chronic cortisol elevation drives more persistent changes: degradation of the ceramide layer that maintains the skin barrier, suppression of the regulatory T cells (Tregs) that control skin inflammatory responses, and activation of the NF-kB inflammatory pathway that drives cytokine production in acne and rosacea.
Thyroid dysfunction and skin
Thyroid hormones regulate the rate of skin cell turnover, sebaceous gland activity and collagen synthesis throughout the dermis. Hypothyroidism reduces keratinocyte proliferation rate, producing the dry, rough, thickened skin characteristic of inadequate thyroid function. The reduced metabolic rate of hypothyroidism also reduces sweating, decreases sebaceous gland activity and reduces the availability of skin-supporting nutrients through impaired gastrointestinal absorption.
Subclinical hypothyroidism — defined as elevated TSH with normal free T4 — produces significant skin changes despite falling within the laboratory reference range. This is clinically important because standard GP panels frequently measure TSH alone, reporting a result within range while the patient experiences the full spectrum of hypothyroid skin symptoms. A complete thyroid assessment including free T3, free T4, reverse T3, TPO antibodies and TG antibodies is required to identify the subclinical and autoimmune thyroid dysfunction that drives significant skin changes.
Post-pill hormonal skin changes
The contraceptive pill suppresses endogenous LH and FSH production, reducing ovarian androgen and oestrogen production and increasing hepatic SHBG synthesis. On the pill, elevated SHBG binds free androgens, reducing sebum production and typically improving acne. When the pill is discontinued, ovarian hormone production resumes — but SHBG levels remain suppressed for an extended period (up to 12 months in some individuals), producing a window of elevated free androgens and dramatically worsened acne that was not present before commencing contraception.
A 2021 study in Contraception found that post-pill SHBG suppression persisted for a mean of 7.4 months following cessation of combined oral contraceptives. During this window, management of post-pill acne requires addressing free androgen excess, supporting SHBG recovery through insulin sensitivity optimisation, and managing the oestrogen deficiency that frequently accompanies the hormonal transition.
Clinical investigation — what a hormonal skin assessment includes
A complete hormonal skin assessment in naturopathic practice includes full androgen panel (total and free testosterone, DHEA-S, DHT, SHBG, androstenedione), oestrogen and progesterone assessment timed to cycle phase, fasting insulin and HOMA-IR, full thyroid panel (TSH, free T3, free T4, reverse T3, TPO and TG antibodies) and a four-point salivary cortisol rhythm. The specific panel is adjusted to the clinical presentation — a post-pill case requires different testing to a perimenopausal case — and results are interpreted in the context of the full clinical history rather than against reference ranges in isolation.
Is a hormonal driver behind your skin condition?
A hormonal skin consultation identifies the specific hormonal drivers of your presentation and builds a targeted protocol. Every enquiry begins with a complimentary 15-minute Discovery Call.
Book a complimentary Discovery Call Take the free skin assessmentReferences
- Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne. Archives of Dermatology. 1999;135(9):1041-1045.
- Smith RN, Mann NJ, Braue A, et al. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. American Journal of Clinical Nutrition. 2007;86(1):107-115.
- Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Archives of Dermatology. 2005;141(3):333-338.
- Verdier-Sevrain S, Bonte F, Gilchrest B. Biology of estrogens in skin: implications for skin aging. Experimental Dermatology. 2006;15(2):83-94.
- Thornton MJ. Estrogens and aging skin. Dermato-Endocrinology. 2013;5(2):264-270.
- Zouboulis CC, Degitz K. Androgen action on human skin — from basic research to clinical significance. Experimental Dermatology. 2004;13 Suppl 4:5-10.
- Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. Journal of Molecular Medicine. 2006;84(1):75-87.
- Plavan PD, Reznichenko OA, Bodnarchuk I. Post-pill amenorrhea and subsequent fertility: impact on SHBG and free androgens. Contraception. 2021;103(5):315-320.
- Farage MA, Miller KW, Elsner P, Maibach HI. Characteristics of the aging skin. Advances in Wound Care. 2013;2(1):5-10.
- Khunger N, Kumar C. A clinico-epidemiological study of adult acne: is it different from adolescent acne? Indian Journal of Dermatology, Venereology and Leprology. 2012;78(3):335-341.